CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced a $250 million underwritten public offering of common stock on March 16, 2026, with Jefferies, Piper Sandler, Cantor, Barclays and Wedbush acting as underwriters and holding a 30‑day option to purchase an additional $37.5 million of shares at the offering price.
The company also released its Q4 2025 earnings, reporting an earnings per share of –$0.22 versus an analyst estimate of –$0.09, and revenue of $0.66 million against an estimate of $8.06 million. Revenue fell sharply from $38.09 million in the same quarter of 2024, reflecting the absence of commercial sales and the heavy investment in research and development that characterizes the company’s current stage.
The earnings miss is largely attributable to the company’s continued focus on clinical development, which has kept operating expenses high while revenue remains limited to a small amount of product sales and milestone payments. The year‑over‑year revenue decline underscores the company’s reliance on future clinical milestones rather than current sales revenue.
Proceeds from the offering will be directed toward advancing Varseta‑M, the company’s lead EpCAM‑targeted antibody‑drug conjugate, and other pipeline programs, as well as supporting capital expenditures, working capital and general corporate purposes. The capital raise is intended to extend the company’s cash runway as it prepares for the next phase of clinical development.
CEO Sean McCarthy emphasized that the positive Phase 1 data for Varseta‑M—showing a 32% confirmed overall response rate at 10 mg/kg—provides a strong clinical catalyst. He noted that the company’s priority in 2026 is to align with the FDA on a registrational path for Varseta‑M in late‑line colorectal cancer and to accelerate combination studies in earlier lines.
Investors responded positively to the announcement, with the primary driver being the encouraging Phase 1 results for Varseta‑M. The market’s enthusiasm reflects confidence in the company’s clinical strategy and the potential of its lead asset, despite the earnings miss and revenue decline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.